Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김경진 | * |
dc.date.accessioned | 2024-02-06T16:31:23Z | - |
dc.date.available | 2024-02-06T16:31:23Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 0021-9150 | * |
dc.identifier.other | OAK-34485 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/267077 | - |
dc.description.abstract | Background and aims: Whether the effect of a combination strategy rather than increasing doses of one drug to lower low-density lipoprotein cholesterol (LDL-C) levels is consistent across baseline LDL-C levels remains uncertain. Methods: In the RACING trial, which showed a non-inferiority of moderate-intensity statin with ezetimibe (rosuvastatin 10 mg with ezetimibe 10 mg) to high-intensity statin (rosuvastatin 20 mg) for the primary outcome (3-year composite of cardiovascular death, major cardiovascular event, or stroke), the heterogeneity in treatment effect according to baseline LDL-C levels was assessed for the primary and secondary outcomes (clinical efficacy and safety). Results: Of 3780 participants, 2817 participants (74.5%) had LDL-C <100 mg/dL, and 963 participants (25.5%) had LDL-C ≥100 mg/dL. The treatment effect of combination therapy versus high-intensity statin monotherapy was similar among the lower LDL-C subset (8.8% vs. 10.2%; hazard ratio [HR] 0.85, 95% confidence interval [CI] 0.67 to 1.08, p = 0.19) and the higher LDL-C subset (10.8% vs. 9.6 %; HR 1.14, 95% CI 0.76 to 1.7, p = 0.53) without a significant interaction (interaction p = 0.22). Of the secondary outcomes, the 1-, 2-, and 3-year achievement of LDL-C <70 mg/dL was greater in the combination therapy group regardless of baseline LDL-C levels. Conclusions: Among ASCVD patients, there was no heterogeneity in the effect of moderate-intensity statin plus ezetimibe combination therapy in the higher and lower baseline LDL-C levels for the 3-year composite of cardiovascular outcomes. © 2023 Elsevier B.V. | * |
dc.language | English | * |
dc.publisher | Elsevier Ireland Ltd | * |
dc.subject | Atherosclerosis | * |
dc.subject | Ezetimibe | * |
dc.subject | Hydroxymethylglutaryl-CoA reductase inhibitors | * |
dc.title | Moderate-intensity statin plus ezetimibe vs high-intensity statin according to baseline LDL-C in the treatment of atherosclerotic cardiovascular disease: A post-hoc analysis of the RACING randomized trial | * |
dc.type | Article | * |
dc.relation.volume | 386 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | Atherosclerosis | * |
dc.identifier.doi | 10.1016/j.atherosclerosis.2023.117373 | * |
dc.identifier.wosid | WOS:001125514800001 | * |
dc.identifier.scopusid | 2-s2.0-85177879871 | * |
dc.author.google | Lee | * |
dc.author.google | Bom | * |
dc.author.google | Hong | * |
dc.author.google | Sung-Jin | * |
dc.author.google | Rha | * |
dc.author.google | Seung-Woon | * |
dc.author.google | Heo | * |
dc.author.google | Jung Ho | * |
dc.author.google | Hur | * |
dc.author.google | Seung-Ho | * |
dc.author.google | Choi | * |
dc.author.google | Hyun Hee | * |
dc.author.google | Kim | * |
dc.author.google | Kyung-Jin | * |
dc.author.google | Ju Han | * |
dc.author.google | Hyun Kuk | * |
dc.author.google | Ung | * |
dc.author.google | Yu Jeong | * |
dc.author.google | Yong-Joon | * |
dc.author.google | Seung-Jun | * |
dc.author.google | Ahn | * |
dc.author.google | Chul-Min | * |
dc.author.google | Ko | * |
dc.author.google | Young-Guk | * |
dc.author.google | Byeong-Keuk | * |
dc.author.google | Donghoon | * |
dc.author.google | Myeong-Ki | * |
dc.author.google | Jang | * |
dc.author.google | Yangsoo | * |
dc.author.google | Jung-Sun | * |
dc.contributor.scopusid | 김경진(57190021870) | * |
dc.date.modifydate | 20240426120924 | * |